Impact News +++ Street sours on Replimune as stock hits all-time low on melanoma drug rejection (SeekingAlpha) +++ REPLIMUNE Aktie +4,10%

REGENERON Aktie

>REGENERON Aktienkurs

638.3 EUR (TradegateBSX)

Ask: 639.4 EUR / 100 Stück

Bid: 637.2 EUR / 100 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: -3,2%

1 Monat: -4,6%

3 Monate: -7,4%

6 Monate: +29,8%

1 Jahr: +29,2%

laufendes Jahr: -4,7%

>REGENERON Aktie

Name:

REGENERON PHARMAC.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75886F1075 / 881535

Symbol/ Ticker:

RGO (Frankfurt) / REGN (NASDAQ)

Kürzel:

FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN

Index:

S&P500, Nasdaq100

Webseite:

http://www.regeneron.com/

Profil:

Regeneron Pharmaceuticals discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company operates across multiple therapeutic areas, with flagship products including Eylea and Eylea HD for eye dis..
>Volltext..

Marktkapitalisierung:

69225.5 Mio. EUR

Unternehmenswert:

64434.72 Mio. EUR

Umsatz:

12233.22 Mio. EUR

EBITDA:

3621.21 Mio. EUR

Nettogewinn:

3842.28 Mio. EUR

Gewinn je Aktie:

36.78 EUR

Schulden:

2535.45 Mio. EUR

Liquide Mittel:

2664.24 Mio. EUR

Operativer Cashflow:

4246.56 Mio. EUR

Bargeldquote:

1.97

Umsatzwachstum:

-10.98%

Gewinnwachstum:

-10.02%

Dividende je Aktie:

3.19 EUR

Dividendenrendite:

0.47%

Dividendenschätzung:

0.49%

Div. Historie:

20.02.26 - 0.798906€
20.11.25 - 0.76287204€

>weitere anzeigen...

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 77.727 USD.

Suchwörter:

REGENERON

Letzte Datenerhebung:

13.04.26

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Aktien: 103.9 Mio. St.

Frei handelbar: 97.93%

Leerverk. Aktien: 2.45%

Rückkaufquote: 3.45%

Mitarbeiter: 15410

Umsatz/Mitarb.: 0.79 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 19.9%

Bewertung:

KGV: 17.8

KGV lG: 16.29

KUV: 5.75

KBV: 2.5

PEG-Ratio: 2.16

EV/EBITDA: 17.79

Rentabilität:

Bruttomarge: 81.56%

Gewinnmarge: 31.41%

Operative Marge: 25.81%

Managementeffizenz:

Gesamtkaprendite: 11.49%

Eigenkaprendite: 14.87%

>REGENERON Peer Group

Gesundheit, Augenmedizin, Lungenerkrankungen & -behandlung/ Asthma, Hauterkrankungen & -behandlung/ Dermatologie, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Herz-Kreislauf- Behandlung/ Kardiologie

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

13.04.26 - 14:33	Regeneron inks deal with Telix for radiopharmaceutical therapies (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.04.26 - 13:18	Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies (AFX)
	CANBERA (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commercialize next generation radiop......

13.04.26 - 13:00	Telix and Regeneron to co-develop radiopharmaceutical therapies (PBR)
	Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global The post Telix and Regeneron to co-develop radiopharmaceutical therapies appeared first on Pharmaceutical Business review....

13.04.26 - 12:39	Regeneron und Sanofi bekommen Dupixent-Zulassung für Kinder mit CSU (Dow Jones)
	Von Colin Kellaher DOW JONES--Regeneron Pharmaceuticals und Sanofi haben für ihren Blockbuster-Entzündungshemmer Dupixent eine erweiterte europäische Zulassung für jüngere Patienten erhalten, ......

13.04.26 - 12:33	Telix and Regeneron Announce Strategic Radiopharma Collaboration (GlobeNewswire EN)
	MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies....

13.04.26 - 12:33	Regeneron and Telix Announce Strategic Radiopharma Collaboration (GlobeNewswire EN)
	Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model ...

13.04.26 - 08:01	Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU (AFX)
	PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) on Monday said the European Commission has approved Dupixent for treating moderate-to-severe chronic spontaneous urtica......

13.04.26 - 07:03	Press Release: Sanofi and Regeneron′s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria (GlobeNewswire EN)
	Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria...

13.04.26 - 05:54	Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies (AFX)
	CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) and Regeneron Pharmaceuticals, Inc. (REGN) have announced a collaboration to jointly develop and commercialize next-generation radio......

13.04.26 - 01:24	Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal (Fool)
	Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies. The post Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal appeared first on The Motley Fool Australia....

09.04.26 - 16:18	A catalyst-rich biotech may be poised to resume its recovery. Use options to take advantage (CNBC)
	Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas....

08.04.26 - 13:36	Regeneron expects ~$102M in Q1 pre-tax IPR&D charges (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.04.26 - 22:46	Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval (Zacks)
	REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales....

06.04.26 - 19:45	All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy (Zacks)
	Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

05.04.26 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 77727 USD (Insiderkauf)
	Ryan, Arthur F. - Aufsichtsrat - Tag der Transaktion: 2026-04-01...

03.04.26 - 19:45	Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
	Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

02.04.26 - 22:33	TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions (PR Newswire)
	Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will......

02.04.26 - 22:33	Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions (GlobeNewswire EN)
	Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data...

02.04.26 - 20:36	Regeneron says it expects to avoid new US pharma tariffs (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.04.26 - 19:30	Regeneron gains approval of every 20 week dosing for Eylea HD (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Mann soll an sich selber meiden, / Was er nicht mag an andern leiden. - Sprichwort Arabisch

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram